Your browser doesn't support javascript.
loading
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.
Mayer, Flavia; Faglioni, Laura; Agabiti, Nera; Fenu, Susanna; Buccisano, Francesco; Latagliata, Roberto; Ricci, Roberto; Spiriti, Maria Antonietta Aloe; Tatarelli, Caterina; Breccia, Massimo; Cimino, Giuseppe; Fianchi, Luana; Criscuolo, Marianna; Gumenyuk, Svitlana; Mancini, Stefano; Maurillo, Luca; Nobile, Carolina; Niscola, Pasquale; Piccioni, Anna Lina; Tafuri, Agostino; Trapè, Giulio; Andriani, Alessandro; De Fabritiis, Paolo; Voso, Maria Teresa; Davoli, Marina; Zini, Gina.
Affiliation
  • Mayer F; Department of Epidemiology, Lazio Regional Health Service(Italy).
  • Faglioni L; Hematology Dep. Az. Osp. San Giovanni-Addolorata Rome(Italy).
  • Agabiti N; Department of Epidemiology, Lazio Regional Health Service(Italy).
  • Fenu S; Hematology Dep. Az. Osp. San Giovanni-Addolorata Rome(Italy).
  • Buccisano F; Hematology Unit Tor Vergata University, Rome(Italy).
  • Latagliata R; Dep of Cellular Biotechnology and Hematology, University "La Sapienza" Rome (Italy).
  • Ricci R; Dep of Cellular Biotechnology and Hematology, University "La Sapienza" Rome (Italy).
  • Spiriti MAA; Hematology Unit Sant' Andrea Univ. "La Sapienza " Rome (Italy).
  • Tatarelli C; Hematology Unit Sant' Andrea Univ. "La Sapienza " Rome (Italy).
  • Breccia M; Dep of Cellular Biotechnology and Hematology, University "La Sapienza" Rome (Italy).
  • Cimino G; Dep. of Cellular Biotechnology and Hematology, University of Rome "Sapienza"-Polo Pontino, Latina(Italy).
  • Fianchi L; Hematology Institute Università Cattolica del Sacro Cuore Rome (Italy).
  • Criscuolo M; Hematology Institute Università Cattolica del Sacro Cuore Rome (Italy).
  • Gumenyuk S; Hematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute Rome (Italy).
  • Mancini S; Hematology Unit Az. Osp. San Camillo-Forlanini, Rome (Italy).
  • Maurillo L; Hematology Unit Tor Vergata University, Rome(Italy).
  • Nobile C; Hematology Dep. Campus Biomedico, Rome (Italy).
  • Niscola P; Hematology Unit Az. Osp. Sant Eugenio Rome (Italy).
  • Piccioni AL; Hematology Unit Az. Osp. Sandro Pertini, Rome (Italy).
  • Tafuri A; Hematology Unit Sant' Andrea Univ. "La Sapienza " Rome (Italy).
  • Trapè G; Hematology Unit Az. Osp. Belcolle Viterbo (Italy).
  • Andriani A; Ospedale Nuova Regina Margherita, Rome (Italy).
  • De Fabritiis P; Hematology Unit Az. Osp. Sant Eugenio Rome (Italy).
  • Voso MT; Hematology Unit Tor Vergata University, Rome(Italy).
  • Davoli M; Department of Epidemiology, Lazio Regional Health Service(Italy).
  • Zini G; Hematology Institute Università Cattolica del Sacro Cuore Rome (Italy).
Mediterr J Hematol Infect Dis ; 9(1): e2017046, 2017.
Article in En | MEDLINE | ID: mdl-28698789
Data on Myelodysplastic Syndromes (MDS) are difficult to collect by cancer registries because of the lack of reporting and the use of different classifications of the disease. In the Lazio Region, data from patients with a confirmed diagnosis of MDS, treated by a hematology center, have been collected since 2002 by the Gruppo Romano-Laziale Mielodisplasie (GROM-L) registry, the second MDS registry existing in Italy. This study aimed at evaluating MDS medical miscoding during hospitalizations, and patients' survival. For these purposes, we selected 644 MDS patients enrolled in the GROM-L registry. This cohort was linked with two regional health information systems: the Hospital Information System (HIS) and the Mortality Information System (MIS) in the 2002-2012 period. Of the 442 patients who were hospitalized at least once during the study period, 92% had up to 12 hospitalizations. 28.5% of patients had no hospitalization episodes scored like MDS, code 238.7 of the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). The rate of death during a median follow-up of 46 months (range 0.9-130) was 45.5%. Acute myeloid leukemia (AML) was the first cause of mortality, interestingly a relevant portion of deaths is due to cerebro-cardiovascular events and second tumors. This study highlights that MDS diagnosis and treatment, which require considerable healthcare resources, tend to be under-documented in the HIS archive. Thus we need to improve the HIS to better identify information on MDS hospitalizations and outcome. Moreover, we underline the importance of comorbidity in MDS patients' survival.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Mediterr J Hematol Infect Dis Year: 2017 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Mediterr J Hematol Infect Dis Year: 2017 Type: Article